EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA

çabalak, mehmet; Bal, Tayibe

doi:10.31086/tjgeri.2020.185

EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA

Mehmet ÇABALAK, (Hatay Mustafa Kemal Üniversitesi, Bulaşıcı Hastalık ve Klinik Mikrobiyoloji, HATAY, Türkiye)

Tayibe BAL (Hatay Mustafa Kemal Üniversitesi, Bulaşıcı Hastalık ve Klinik Mikrobiyoloji, HATAY, Türkiye)

Türk Geriatri Dergisi

1 0

Yıl: 2020 Cilt: 23 Sayı: 4 Sayfa Aralığı: 473 - 481 Metin Dili: İngilizce DOI: 10.31086/tjgeri.2020.185 İndeks Tarihi: 04-11-2021

EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA

Öz:

Introduction: Objectives: Elderly cases have not been adequately representedin clinical trials with respect to chronic hepatitis C treatment. Extremely limited realworld data is available on new direct-acting antivirals in elderly patients. Herein, weaim to evaluate real-world data on new direct-acting antivirals used in the treatmentof chronic hepatitis C virus.Materials and Method: Medical records of 122 patients who started treatmentwith new direct-acting antivirals between January 2018 and December 2019 owingto chronic hepatitis C virus infection were analyzed retrospectively. Patients weredivided into two age groups: those younger than 65 years and those aged 65 andolder. Sustained virological response at 12 week rates were compared between thetwo groups. Sustained virological response at 12 week treatment efficacy analyseswere performed with both modified intention to tract and per protocol.Results: Sustained virological response in the 12th week post treatment wassimilar in both elderly patients and younger patients. Per protocol analysis was97.6% (42/43) vs. 100% (56/56) and modified intention to tract analysis was 91.3%(43/45) vs. 91.8% (56/61), respectively. The most common genotype of patientsaged 65 years and older were 1b 80%, and the most common genotype of patientsyounger than 65 years was 1b 57%.Conclusion: In the present study, Sustained virological response rates weresimilar in elderly patients compared to younger patients; however, very limitedinformation is available on the effectiveness and safety of new, recently approveddirect-acting antivirals in the elderly population.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. World Health Organization. Global Hepatitis Report; 2017. (Internet). Available from: https://www.who.int/ hepatitis/publications/global-hepatitis-report2017/ en/. Accessed: 06.08.2020.
2. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571–83. (DOI:10.1016/s0140- 6736(11)61097-0).
3. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44(Suppl 1):20-9. (PMID: 14681338).
4. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55(1):S10-5. (PMID: 22715208).
5. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; (11):1020-6. (PMID: 26163105).
6. Yang Z, Zhuang L, Yang L, et al. Efficacy and safety of peginterferon plus ribavirin for patients aged ≥65 years with chronic hepatitis C: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2014; 38:(Suppl 4):440–50 (PMID:24176812).
7. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000; 32(1):111–5. (PMID:10869297).
8. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006; 101:1260-7. (PMID: 16771947).
9. Saab S, Rheem J, Sundaram V. Hepatitis C infection in the elderly. Dig Dis Sci 2015; 60(11):3170-80. (PMID:26008618).
10. Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010; 30(4):527-37. (PMID:19523048).
11. El-Serag H, Kramer J, Duan Z, Kanwai F. Epidemiology and outcomes of hepatitis C infection in elderly US veterans. J Viral Hepat 2016; 23(9):687-96. (PMID:27040447).
12. Yang Z, Zhuang L, Yang L, et al. Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2014; 38(4):440-50. (PMID: 24176812).
13. Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir/ sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology 2016; 63(4):1112-9. (PMID:26704693).
14. Dultz G, Müller T, Petersen J, et al. Effectiveness and safety of direct-acting antiviral combination therapies for treatment of hepatitis C virus in elderly patients: results from the German Hepatitis C Registry. Drugs Aging 2018; 35(9):843–57. (PMID:30084012).
15. Lens S, Fernandez I, Rodriguez-Tajes S, et al. Interferon-free therapy in elderly patients with advanced liver disease. Am J Gastroenterol 2017; 112(9):1400– 9. (PMID:28585554).
16. Su F, Beste LA, Green PK, Berry K, Ioannou GN. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol 2017; 29(6):686–93. (PMID:28195877).
17. Sherigar JM, Gayam V, Khan A, et al. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2017; 29(7):767-76. (PMID:28346233).
18. Gane E, Poordad F, Wang S, et al. High Efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology 2016; 151(4):651–659. (PMID:27456384).
19. Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 2017; 67(2):263–71. (PMID:28412293).
20. Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017; 66(2):389–97. (PMID:28128852).
21. Foster GR, Asselah T, Kopecky-Bromberg S, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One 2019; 14(1):e0208506 .(PMID:30601818).
22. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015; 42(5):559-73. (PMID:26113432).
23. Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat 2017; 24(1):22-7. (PMID: 27730717).

APA	çabalak m, Bal T (2020). EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. , 473 - 481. 10.31086/tjgeri.2020.185
Chicago	çabalak mehmet,Bal Tayibe EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. (2020): 473 - 481. 10.31086/tjgeri.2020.185
MLA	çabalak mehmet,Bal Tayibe EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. , 2020, ss.473 - 481. 10.31086/tjgeri.2020.185
AMA	çabalak m,Bal T EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. . 2020; 473 - 481. 10.31086/tjgeri.2020.185
Vancouver	çabalak m,Bal T EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. . 2020; 473 - 481. 10.31086/tjgeri.2020.185
IEEE	çabalak m,Bal T "EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA." , ss.473 - 481, 2020. 10.31086/tjgeri.2020.185
ISNAD	çabalak, mehmet - Bal, Tayibe. "EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA". (2020), 473-481. https://doi.org/10.31086/tjgeri.2020.185

APA	çabalak m, Bal T (2020). EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. Türk Geriatri Dergisi, 23(4), 473 - 481. 10.31086/tjgeri.2020.185
Chicago	çabalak mehmet,Bal Tayibe EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. Türk Geriatri Dergisi 23, no.4 (2020): 473 - 481. 10.31086/tjgeri.2020.185
MLA	çabalak mehmet,Bal Tayibe EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. Türk Geriatri Dergisi, vol.23, no.4, 2020, ss.473 - 481. 10.31086/tjgeri.2020.185
AMA	çabalak m,Bal T EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. Türk Geriatri Dergisi. 2020; 23(4): 473 - 481. 10.31086/tjgeri.2020.185
Vancouver	çabalak m,Bal T EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA. Türk Geriatri Dergisi. 2020; 23(4): 473 - 481. 10.31086/tjgeri.2020.185
IEEE	çabalak m,Bal T "EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA." Türk Geriatri Dergisi, 23, ss.473 - 481, 2020. 10.31086/tjgeri.2020.185
ISNAD	çabalak, mehmet - Bal, Tayibe. "EFFECTIVENESS OF ORAL DIRECT ACTING ANTIVIRALS IN ELDERLY CHRONIC HEPATITIS C PATIENTS: REAL-WORLD DATA". Türk Geriatri Dergisi 23/4 (2020), 473-481. https://doi.org/10.31086/tjgeri.2020.185